Glaucoma Treatment Market Size

Glaucoma Treatment Market Size

Glaucoma Treatment Market size exceeded USD 5.5 billion in 2021 and is expected to witness over 3.2% CAGR from 2022 to 2028. Rising prevalence of glaucoma diseases and growing demand for advanced therapeutic interventions are some of the major factors that facilitate the market growth. According to the World Glaucoma Association, around 76 million people were suffering from glaucoma in 2020.

Moreover, primary open angle glaucoma (POAG) is the predominant type of glaucoma in the population. In 2020, more than 57.5 million people worldwide were affected by POAG with a global prevalence of 2.2%. Thus, rising glaucoma disease burden is anticipated to offer lucrative growth opportunities in the market. Furthermore, the growing geriatric population that is prone to age-related diseases is another prominent factor that will accelerate glaucoma treatment industry growth over the estimated time period.

The COVID-19 pandemic had slightly negative impact on the sales of glaucoma treatment market owing to the imposition of preventive lockdown in several economies. Additionally, prioritization and mobilization of all resources to COVID 19 patients due to shortage of healthcare infrastructure. Also, numerous ophthalmology departments were converted into COVID-19 wards which restricted the follow-ups of glaucoma patients. Furthermore, fewer patient visits to the clinical settings owing to fear of infection among older adults have resulted in lessened demand for market. However, adoption of telemedicine platforms during pandemic helped the patients to get access to the treatment on time which impelled the overall industry growth.

Glaucoma is a disorder of progressive optic neuropathies that is caused by degeneration of retinal nerve fiber layers and retinal ganglion cells that may lead to changes in the optical nerve head. The major risk factor is that high intraocular pressure (IOP) can damage the optic nerve and continued damage to this structure may lead to irreversible visual field defects, visual impairment, and blindness. Glaucoma is the leading cause of irreversible blindness across the world. Risk factors include gender, race, myopia, family history, genetics, age and frailty, vasospasm, smoking, systemic hypotension and hypertension, obstructive sleep apnea syndrome, migraine, consumption of steroids, and most significantly, increased IOP. These factors will spur the demand for glaucoma treatment market.

Recent advancements in therapeutic interventions will fuel the market momentum

Continuous technological advancements in ophthalmology field are one of the major factors fuelling the glaucoma treatment market outlook. Increasing demand for advanced surgical procedures will propel industry growth potential. Moreover, advancements in optometric care such as medical imaging, selective laser trabeculoplasty (SLT), optical coherence tomography (OCT), visual fields, microinvasive glaucoma surgery (MIGS) and progression analysis software will boost patient preference. Additionally, integration of laser treatments as first-line therapy along with medication to treat glaucoma will proliferate the market size.